Goldman J, Tamayo R C, Whitehouse F W, Kahkonen D M
Diabetes Care. 1984 May-Jun;7 Suppl 1:106-12.
The extrapancreatic effects of the sulfonylurea drug glyburide in insulin-dependent diabetes mellitus were examined in a double-blind, prospective study involving 28 patients. Administration of glyburide in addition to the usual diet and insulin dose for 6 mo led to a minimal and transient decrease in hemoglobin A1c and total glycosylated hemoglobin. Insulin receptors of peripheral monocytes were initially normal in both number and affinity in this group of insulin-dependent diabetic patients, but, after 6 mo of glyburide therapy, binding to insulin receptors declined at the lower insulin concentration range without falling out of the normal range. No changes could be demonstrated in plasma triglycerides, cholesterol, or lipoprotein-cholesterol fractions. We conclude that the extrapancreatic effects of the sulfonylurea glyburide in insulin-deficient diabetic subjects are small. These effects may be mediated through a postinsulin receptor mechanism.
在一项涉及28例患者的双盲前瞻性研究中，对磺脲类药物格列本脲在胰岛素依赖型糖尿病中的胰腺外效应进行了研究。在常规饮食和胰岛素剂量基础上，给予格列本脲6个月，导致糖化血红蛋白A1c和总糖化血红蛋白出现最小程度的短暂下降。在这组胰岛素依赖型糖尿病患者中，外周单核细胞的胰岛素受体数量和亲和力最初均正常，但在格列本脲治疗6个月后，在较低胰岛素浓度范围内，与胰岛素受体的结合下降，但未超出正常范围。血浆甘油三酯、胆固醇或脂蛋白胆固醇组分未显示出变化。我们得出结论，磺脲类格列本脲在胰岛素缺乏的糖尿病患者中的胰腺外效应较小。这些效应可能通过胰岛素受体后机制介导。
